{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:58:35Z","timestamp":1790359115946,"version":"4.1.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>In 2017, the US Food and Drug Administration (FDA) approved a monthly injectable form of buprenorphine, extended-release buprenorphine; published data show that extended-release buprenorphine is effective compared with no treatment, but its current cost is higher and current retention is lower than that of transmucosal buprenorphine. Preliminary research suggests that extended-release buprenorphine may be an important addition to treatment options, but the cost-effectiveness of extended-release buprenorphine compared with transmucosal buprenorphine remains unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the cost-effectiveness of extended-release buprenorphine compared with transmucosal buprenorphine.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This economic evaluation used a state transition model starting in 2019 to simulate the lifetime of a closed cohort of individuals with OUD presenting for evaluation for opioid agonist treatment with buprenorphine. The data sources used to estimate model parameters included cohort studies, clinical trials, and administrative data. The model relied on pharmaceutical costs from the Federal Supply Schedule and health care utilization costs from published studies. Data were analyzed from September 2021 to January 2023.<\/jats:p><\/jats:sec>Interventions<\/jats:title>No treatment, treatment with transmucosal buprenorphine, or treatment with extended-release buprenorphine.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Mean lifetime costs per person, discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).<\/jats:p><\/jats:sec>Results<\/jats:title>The simulated cohort included 100\u202f000 patients with OUD receiving (61% male; mean [SD] age, 38 [11] years) or not receiving medication treatment (58% male, mean [SD] age, 48 [18] years). Compared with no medication treatment, treatment with transmucosal buprenorphine yielded an ICER of $19\u202f740 per QALY. Compared with treatment with transmucosal buprenorphine, treatment with extended-release buprenorphine yielded lower effectiveness by 0.03 QALYs per person at higher cost, suggesting that treatment with extended-release buprenorphine was dominated and not preferred. In probabilistic sensitivity analyses, treatment with transmucosal buprenorphine was the preferred strategy 60% of the time. Treatment with extended-release buprenorphine was cost-effective compared with treatment with transmucosal buprenorphine at a $100\u202f000 per QALY willingness-to-pay threshold only after substantial changes in key parameters.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation of extended-release buprenorphine compared with transmucosal buprenorphine for the treatment of OUD, extended-release buprenorphine was not associated with efficient allocation of limited resources when transmucosal buprenorphine was available. Future initiatives should aim to improve retention rates or decrease costs associated with extended-release buprenorphine.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.29583","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T15:04:50Z","timestamp":1694617490000},"page":"e2329583","source":"Crossref","is-referenced-by-count":20,"title":["Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Juliet M.","family":"Flam-Ross","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"},{"name":"Now with London School of Hygiene and Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Marsh","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Weitz","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Savinkina","sequence":"additional","affiliation":[{"name":"Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Wang","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. W. M. A.","family":"Madushani","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake R.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Barocas","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine and Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Walley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula A.","family":"Chrysanthopoulou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University School of Public Health, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"},{"name":"Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"},{"name":"Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina A.","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts"},{"name":"Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"3","key":"zoi230852r2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: the foundation of recovery.","volume":"31","author":"Bart","year":"2012","journal-title":"J Addict Dis"},{"issue":"1","key":"zoi230852r3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/add.2011.106.issue-1","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"zoi230852r4","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"zoi230852r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a Cascade of Care for responding to the opioid epidemic.","volume":"45","author":"Williams","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"10118","key":"zoi230852r6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736(17)32893-3","article-title":"Medications for opioid use disorder: bridging the gap in care.","volume":"391","author":"Volkow","year":"2018","journal-title":"Lancet"},{"key":"zoi230852r7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"zoi230852r8","author":"Alderks","year":"2017"},{"key":"zoi230852r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108764","article-title":"Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.","volume":"225","author":"Morgan","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi230852r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103788","article-title":"Can a new formulation of opiate agonist treatment alter stigma?: place, time and things in the experience of extended-release buprenorphine depot.","volume":"107","author":"Treloar","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi230852r15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/dar.v42.4","article-title":"Exploring patient experience and satisfaction with depot buprenorphine formulations: a mixed-methods study.","volume":"42","author":"Allen","year":"2023","journal-title":"Drug Alcohol Rev"},{"issue":"33","key":"zoi230852r16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/adaw.v34.33","article-title":"Spending bill includes X-waiver elimination, more.","volume":"34","author":"Knopf","year":"2022","journal-title":"Alcohol Drug Abuse Wkly"},{"issue":"6","key":"zoi230852r17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.","volume":"27","author":"Schackman","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi230852r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37259","article-title":"Projected estimates of opioid mortality after community-level interventions.","volume":"4","author":"Linas","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi230852r19","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/add.v117.9","article-title":"Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.","volume":"117","author":"Savinkina","year":"2022","journal-title":"Addiction"},{"issue":"2","key":"zoi230852r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi230852r21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force\u20133.","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"issue":"4","key":"zoi230852r22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide.","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"issue":"10118","key":"zoi230852r23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"zoi230852r25","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2105\/AJPH.2018.304673","article-title":"Estimated prevalence of opioid use disorder in Massachusetts, 2011-2015: a capture-recapture analysis.","volume":"108","author":"Barocas","year":"2018","journal-title":"Am J Public Health"},{"key":"zoi230852r28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.drugalcdep.2015.11.011","article-title":"Health behaviors of young adult heroin injectors in the Seattle area.","volume":"158","author":"Cedarbaum","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi230852r29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse.","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann Intern Med"},{"key":"zoi230852r32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"zoi230852r34","first-page":"526","article-title":"Cost of pharmacotherapy for opioid use disorders following inpatient detoxification.","volume":"24","author":"McCollister","year":"2018","journal-title":"Am J Manag Care"},{"issue":"10","key":"zoi230852r35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183354","article-title":"Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: a pilot randomized controlled trial.","volume":"12","author":"Coffin","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"zoi230852r36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/PHH.0000000000000514","article-title":"Can emergency department, hospital discharge, and death data be used to monitor burden of drug overdose in Rhode Island?","volume":"23","author":"Jiang","year":"2017","journal-title":"J Public Health Manag Pract"},{"issue":"4","key":"zoi230852r38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/add.v111.4","article-title":"Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.","volume":"111","author":"Wittenberg","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"zoi230852r40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/ADM.0000000000000697","volume":"15","author":"Socias","year":"2021","journal-title":"J Addict Med"},{"key":"zoi230852r41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management.","volume":"94","author":"Kenney","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"zoi230852r44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi230852r45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw266","article-title":"Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis C virus genotype 1.","volume":"4","author":"Linas","year":"2016","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zoi230852r46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi230852r47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244401","article-title":"Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: a systematic review with network meta-analyses.","volume":"15","author":"Rice","year":"2020","journal-title":"PLoS One"},{"key":"zoi230852r11","author":"US Department of Veterans Affairs"},{"key":"zoi230852r39","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001","volume-title":"SGD, Russell L.B., Siegel JE, Ganiats T.G. Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016","edition":"2nd ed"},{"key":"zoi230852r1","unstructured":"CDC. Provisional drug overdose death counts. 2022 Accessed October 4, 2022. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi230852r9","unstructured":"Indivior UK Limited. SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use, CIII. Published 2022. Accessed Oct 4, 2022. https:\/\/www.sublocade.com\/Content\/pdf\/prescribing-information.pdf"},{"key":"zoi230852r10","unstructured":"Hikma Pharmaceutical USA Inc. Buprenorphine (bue\u201d pre nor\u2019 feen) Sublingual Tablets CIII. Accessed October 4, 2022. https:\/\/dailymed.nlm.nih.gov\/dailymed\/medguide.cfm?setid=1bf8b35a-b769-465c-a2f8-099868dfcd2f"},{"key":"zoi230852r13","unstructured":"US Food & Drug Administration. FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. Published November 30, 2017. Accessed October 4, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-once-monthly-buprenorphine-injection-medication-assisted-treatment-option-opioid"},{"key":"zoi230852r24","unstructured":"Mass.gov. Massachusetts Public Health Data Warehouse (PHD). Accessed October 4, 2022. https:\/\/www.mass.gov\/public-health-data-warehouse-phd"},{"key":"zoi230852r26","unstructured":"Massachusetts Department of Public Health. An assessment of fatal and nonfatal opioid overdoses in Massachusetts (2011 \u2013 2015). Published August 2017. Accessed October 4, 2022. https:\/\/www.mass.gov\/files\/documents\/2017\/08\/31\/legislative-report-chapter-55-aug-2017.pdf"},{"key":"zoi230852r27","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: detailed tables. Published September 4, 2014. Accessed July 18, 2023. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-DetTabs2013.pdf"},{"key":"zoi230852r30","unstructured":"United States Census Bureau. Decennial census of population and housing datasets. 2010. Accessed October 4, 2022. https:\/\/www.census.gov\/programs-surveys\/decennial-census\/data\/datasets.2010.List_327707051.html#list-tab-List_327707051"},{"key":"zoi230852r31","unstructured":"IBM. IBM MarketScan Research Databases. Published 2021. Accessed October 4, 2022. https:\/\/www.ibm.com\/uk-en\/products\/marketscan-research-databases\/databases"},{"key":"zoi230852r33","unstructured":"National Institute on Drug Abuse. Medications to Treat Opioid Use Disorder Research Report. Published 2021. Accessed July 25, 2023. https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/overview"},{"key":"zoi230852r37","unstructured":"Centers for Disease Control and Prevention. HIV Infection, risk, prevention, and testing behaviors among persons who inject drugs: National HIV Behavioral Surveillance: injection drug use, 23 US cities, 2018. Published February 2020. Accessed July 18, 2023. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-special-report-number-24.pdf"},{"key":"zoi230852r42","unstructured":"US Food and Drug Administration. FDA approves new buprenorphine treatment option for opioid use disorder. Published May 23, 2023. Accessed July 22, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder"},{"key":"zoi230852r43","doi-asserted-by":"crossref","unstructured":"Santos? C. Costa? E, Machado? SR. Uncovering competitive forces in prescription drug markets. Published online March 8, 2023. Accessed July 18, 2023. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4374203","DOI":"10.2139\/ssrn.4374203"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809294\/flamross_2023_oi_230852_1693594856.65174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T15:04:56Z","timestamp":1694617496000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.29583","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}